Kwality Pharmaceuticals share news and announcements
NSE: KPLBSE: 539997Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹3,618.30.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹3,661 Cr1,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 45.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 11.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 27.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 25.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 38,71643.8% delivered
Kwality Pharmaceuticals share news and announcements
373 announcements, routine notices left out, newest first. Page 2 of 8.
Sep 2025
10 Sep · Management
9 Sep · Management
Aug 2025
18 Aug · Kwality Pharma Receives Product Registration For Bleomycin 15 IU In Mexico For Sale And Distribution.
16 Aug · Meeting
16 Aug · Corporate action
16 Aug · Meeting
4 Aug · Board meeting
Meeting on 11 Aug 2025: quarterly results
Jul 2025
May 2025
7 May · Conclusion Of Regulatory Audit For Zimbabwe
6 May · Board meeting
Meeting on 19 May 2025: audited results and quarterly results
Feb 2025
14 Feb · Kwality Pharmaceutical Limited Receives Product Registration Of Cyclophosphamide 1Gm In Mexico
Jan 2025
20 Jan · Board meeting
Meeting on 31 Jan 2025: quarterly results2 Jan · Kwality Pharmaceutical Ltd Receives RCGM Approval To Advance For Pre-Clinical Studies Of Erythropoietin (10,000 IU/Ml)
Dec 2024
24 Dec · Kwality Receives Product Approval For Tamoxifen 20Mg Tablet In South Africa
Nov 2024
26 Nov · Kwality Received Its First Biological Product Permission For Manufacturing And Sale Of Pegylated-Asparaginase
6 Nov · Kwality Pharma Received The Approval For Leuprorelin Acetate For Injectable Suspension As A Site Variation From Greece
Oct 2024
22 Oct · Board meeting
Meeting on 30 Oct 2024: quarterly results
Sep 2024
26 Sep · Management
26 Sep · Meeting
24 Sep · Meeting
Aug 2024
31 Aug · Meeting
31 Aug · Meeting
31 Aug · Corporate action
22 Aug · Legal
Exchange has sought clarification from Kwality Pharmaceuticals Ltd on August 22, 2024, with reference to significant movement in price, in order to ensure that investors have latest ....10 Aug · Results
2 Aug · Board meeting
Meeting on 10 Aug 2024: quarterly results
Jul 2024
17 Jul · KWALITY PHARMA RECEIVED PERU- DIGEMID Approval For Its Generic, Injectable & OSD (Unit -1 In Amritsar) And Oncology, Injectable And OSD (Unit-3 In Himachal Pradesh)